FACIO-SCAPULO-HUMERAL DYSTROPHY
Clinical trials for FACIO-SCAPULO-HUMERAL DYSTROPHY explained in plain language.
Never miss a new study
Get alerted when new FACIO-SCAPULO-HUMERAL DYSTROPHY trials appear
Sign up with your email to follow new studies for FACIO-SCAPULO-HUMERAL DYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Breakthrough drug trial offers hope for rare muscle disease
Disease control Recruiting nowThis study is testing an experimental drug called AOC 1020 for people with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. About 200 participants will receive either the drug or a placebo via IV infusion every six weeks …
Matched conditions: FACIO-SCAPULO-HUMERAL DYSTROPHY
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug enters human testing for rare Muscle-Wasting disease
Disease control Recruiting nowThis early-stage study is testing a new drug called ARO-DUX4 in adults and adolescents with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a genetic condition that causes progressive muscle weakness. The main goal is to check if the drug is safe and how it behaves in the …
Matched conditions: FACIO-SCAPULO-HUMERAL DYSTROPHY
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Mar 16, 2026 15:23 UTC